|
Gefitinib
RIP2 tyrosine kinase inhibitor (Iressa)
Gefitinib (also known as Iressa) is a selective inhibitor of epidermal growth factor (EGFR), a growth factor that plays a pivotal role in the control of cell growth, apoptosis, and angiogenesis. EGFR activation stimulates many complex intracellular signaling pathways, primarily the MEK/ERK and PI3K/AKT pathways [1, 2]. Following EGFR activation, Src tyrosine kinases and STAT downstream signaling have also been well documented [2]. Recent studies demonstrated that Gefitinib can inhibit NOD2-induced cytokine release and NF-kB activation by inhibiting RIP2 (receptor-interacting protein 2) tyrosine phosphylation which is critical for activation of NOD2 downsream signaling pathways [3].
Working concentration: 10 µM
Endotoxin levels: <0.001 EU/µg
Solubility: 100 mM in DMSO
CAS number: 184475-35-2
Molecular weight: 446.9 |